Adalimumab, etanercept, infliximab and abatacept for treating moderate rheumatoid arthritis after conventional DMARDs have failed

Technology appraisal guidance
Reference number: TA715
Published: 14 July 2021

History

Expected publication

Equality Impact Assessment (Guidance development) (PDF 172 KB)

Published:

14 July 2021
Register of interests (PDF 159 KB)

Published:

14 July 2021

Final draft guidance

Final draft guidance
Final appraisal document (PDF 319 KB)

Published:

10 June 2021
Committee papers (PDF 824 KB)

Published:

10 June 2021

Draft guidance

Draft guidance
Appraisal consultation document (PDF version) (PDF 328 KB)

Published:

31 March 2021
Appraisal consultation document (online commenting)
Committee papers (PDF 2.2 MB)

Published:

31 March 2021
Public committee slides (PDF 510 KB)

Published:

31 March 2021

Assessment report sent for information

Assessment report (MSWord 356 KB)

Published:

14 January 2021

Invitation to participate

Final scope (PDF 228 KB)

Published:

03 September 2020
Final stakeholder list (PDF 167 KB)

Published:

03 September 2020